PCY Application No

A. CLASSIFICATION OF SUBJECT M. A. IPC 7 C07C217/18 C07C217/14 A61K31/135

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

Category •	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 04277 A (SPHINX PHARMA CORP) 9 February 1995 (1995-02-09) page 9, last paragraph; page 44, scheme VI	1,33
A .	EP 0 551 662 A (BAYER AG) 21 July 1993 (1993-07-21) abstract; claims 1,7,8	1,33
A .	EP 0 171 209 A (MCNEILAB INC) 12 February 1986 (1986-02-12) page 11, paragraph 4; claim 1	1,33
A	EP 0 146 271 A (MCNEILAB INC) 26 June 1985 (1985-06-26) claims 1,16-19	1,33
	-/	

X Further documents are listed in the continuation of box C.	χ Patent family members are listed in annex.			
Special categories of cited documents: 'A' document defining the general state of the art which is not considered to be of particular relevance 'E' earlier document but published on or after the international filing date 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) 'O' document referring to an oral disclosure, use, exhibition or other means 'P' document published prior to the international filing date but later than the priority date claimed	"T" later document published after the International filing date or priority date and not in conflict with the application but cled to understand the principle or theory underlying the invention. "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone. "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family			
Date of the actual completion of the international search 11 December 2003	Date of mailing of the International search report 23/12/2003			
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni, Fax: (+31-70) 340-3016	Authorized officer . Rufet, J			

International Application No PC 03/03089

A. CLASSIFICATION OF SUBJECT IPC 7 CO7K14/575 GO1N33/68

A61K38/22

C12N15/10

A01K67/027

C12N15/86

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 CO7K A61K

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, CHEM ABS Data

Category *	Citation of document, with indication, where appropriate, of the rel	evant passages	Relevant to claim No.
x	REUBI JEAN CLAUDE ET AL: "Y1-med effect of neuropeptide Y in cance carcinomas as targets" CANCER RESEARCH, vol. 61, no. 11, 1 June 2001 (200 pages 4636-4641, XP001156605 ISSN: 0008-5472	er: Breast	1~5
Y	whole document, abstract, lines 3 page 4640	3/4, esp.	1-41
Y	WO 95 00161 A (UNIV CINCINNATI; BALASUBRAMANIAM AMBIKAIPAKAN (US 5 January 1995 (1995-01-05) Calim 12 and related examples, Tapage 42 ff, Example 5		1-41
X Furti	ner documents are listed in the continuation of box C.	χ Patent family members are listed	in annex.
"A" docume consid "E" earlier of filing d "L" docume which citation "O" docume other of "P" docume	nt which may throw doubts on priority dalm(s) or is cited to establish the publication date of another n or other special reason (as specified) ant referring to an oral disclosure, use, exhibition or	"T" later document published after the Inte or priority date and not in conflict with cited to understand the principle or th Invention "X" document of particular relevance; the cannot be considered novel or cannot involve an inventive step when the dc "Y" document of particular relevance; the cannot be considered to involve an in document is combined with one or ments, such combination being obvio in the art. "&" document member of the same patent	the application but early underlying the claimed invention to considered to coursent is taken alone saimed invention ventive step when the one other such docu-us to a person skilled
Date of the	actual completion of the international search	Date of mailing of the international se	arch report

Name and mailing address of the ISA

20 November 2003

Ruropean Palent Office, P.B. 5818 Palentiaan 2 NL - 2280 HV Rijswijk Tel (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 19/12/2003

Kronester-Frei, A

Authorized officer

International Application No
P 03/03089

	Intion) DOCUMENTS CO. RED TO BE RELEVANT	
Calegory *	Citation of document, with indication, where appropriate, of the relevant passages	 Relevant to claim No.
Υ .	MICHEL MARTIN C ET AL: "XVI. International union of pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors" PHARMACOLOGICAL REVIEWS, vol. 50, no. 1, March 1998 (1998-03), pages 143-150, XP002262056 ISSN: 0031-6997 Table 1, whole document	1-41
Υ .	WAHLESTEDT C ET AL: "NEUROPEPTIDE Y-RELATED PEPTIDES AND THEIR RECEPTORS-ARE THE RECEPTORS POTENTIAL THERAPEUTIC DRUG TARGETS?" ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, ANNUAL REVIEW INC., PALO ALTO, CA, US, vol. 32, 1993, pages 309-352, XP000612055 ISSN: 0362-1642 whole docuemnt, esp. page 312/313, 341ff	1-41
Υ	GEHLERT D R: "SUBTYPES OF RECEPTORS FOR NEUROPEPTIDE Y: IMPLICATIONS FOR THE TARGETING OF THERAPEUTICS" LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 55, no. 8, 1994, pages 551-562, XP000612039 ISSN: 0024-3205 Table 1, page 553, Cardiovascular system, last sentence of first paragraph	1-41
Y	YU A ET AL: "Vitamin E and the Y4 agonist BA-129 decrease prostate cancer growth and production of vascular endothelial growth factor" JOURNAL OF SURGICAL RESEARCH, vol. 105, no. 1, 1 June 2002 (2002-06-01), pages 65-68, XP002262057 ISSN: 0022-4804 Gastriintestinal hormaone peptide, similar to neuropeptide y	1-41
A	BEHR T M ET AL: "IMPROVED PROSPECTS FOR CANCER THERAPY WITH RADIOLABELED ANTIBODY FRAGMENTS AND PEPTIDES?" JOURNAL OF NUCLEAR MEDICINE, SOCIETY OF NUCLEAR MEDICINE. NEW YORK, US, vol. 37, no. 5, May 1996 (1996-05), pages 834-836, XP000978767 ISSN: 0161-5505 the whole document	39

International Application No
PO 03/03089

atogory *	Action) DOCUMENTS COME ARED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
1	WO 02 051857 A (NANDABALAN KRISHNAN ;CHEW ANNE (US); DENTON R REX (US); GENAISSANC) 4 July 2002 (2002-07-04) the whole document	1-41
,		
		·
		·

icformation on patent family members

		indicated on patent name in the most service of the most service o		P	PG 03/03089	
Patent document dted in search report	Publication date		Patent family member(s)		Publication date	
WO 9500161	A	05-01-1995	AU	7174494 A	17-01-1995	
			CA	2165200 A1	05-01-1995	
	•		EP	0707490 A1	24-04-1996	
			JP	11501281 T	02-02-1999	
			WO	9500161 A1	05-01-1995	
			ZA	9404338 A	14-02-1995	

WO 02051857 A 04-07-2002 WO 02051857 A1 04-07-2002

International Application No